Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,031Revenue (TTM) $M175Net Margin (%)14.9Altman Z-Score8.6
Enterprise Value $M977EPS (TTM) $0.5Operating Margin %15.4Piotroski F-Score5
P/E(ttm)44.3Beneish M-Score-1.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book7.310-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales6.15-y EBITDA Growth Rate %--Current Ratio1.7Lower Leverage y-yY
Price/Free Cash Flow37.8y-y EBITDA Growth Rate %-26.9ROA % (ttm)14.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)21.8Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M49.5ROIC % (ttm)37.9Gross Margin Increase y-yN

Gurus Latest Trades with SUPN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SUPNJoel Greenblatt 2016-06-30 Reduce$15.12 - $20.37
$ 20.8318%Reduce -29.04%12,455
SUPNRobert Bruce 2016-03-31 Reduce-0.12%$10.13 - $15.65
$ 20.8360%Reduce -11.78%224,581
SUPNJoel Greenblatt 2016-03-31 Reduce$10.13 - $15.65
$ 20.8360%Reduce -48.08%17,552
SUPNRobert Bruce 2015-12-31 Reduce-0.57%$12.78 - $18.86
$ 20.8335%Reduce -35.48%254,581
SUPNJoel Greenblatt 2015-12-31 Reduce$12.78 - $18.86
$ 20.8335%Reduce -13.63%33,808
SUPNRobert Bruce 2015-09-30 Reduce-1.5%$13.62 - $21.26
$ 20.8312%Reduce -43.19%394,581
SUPNJoel Greenblatt 2015-09-30 Reduce-0.01%$13.62 - $21.26
$ 20.8312%Reduce -55.66%39,142
SUPNGeorge Soros 2015-06-30 Sold Out -0.01%$12.09 - $18.37
$ 20.8347%Sold Out0
SUPNJoel Greenblatt 2015-06-30 Add0.01%$12.09 - $18.37
$ 20.8347%Add 111.74%88,267
SUPNGeorge Soros 2015-03-31 Buy 0.01%$8.18 - $12.09
$ 20.83120%New holding107,308
SUPNJoel Greenblatt 2015-03-31 Buy $8.18 - $12.09
$ 20.83120%New holding41,686
SUPNRobert Bruce 2014-12-31 Add0.68%$7.49 - $9.49
$ 20.83148%Add 73.65%694,581
SUPNRobert Bruce 2014-09-30 Add0.73%$7.99 - $11.13
$ 20.83132%Add 300.00%400,000
SUPNRobert Bruce 2014-06-30 Buy 0.25%$7.32 - $10.85
$ 20.83135%New holding100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SUPN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

SUPN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PATRICK GREGORY SVP, CFO 2016-09-16Sell2,000$25-16.68view
PATRICK GREGORY SVP, CFO 2016-07-14Sell3,395$22-5.32view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2016-04-11Sell30,762$16.4926.32view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-12-09Sell14,238$14.939.8view
BARRETT M JAMESDirector 2015-12-08Sell212,970$14.5643.06view
BARRETT M JAMESDirector 2015-11-25Sell16,179$16.3527.4view
BARRETT M JAMESDirector 2015-11-18Sell93,000$16.6125.41view
BARRETT M JAMESDirector 2015-11-16Sell119,650$16.2428.26view
Bhatt Padmanabh P.Sr. VP of IP, CSO 2015-11-04Sell5,000$19.94.67view
Schwabe Stefan K.F.Executive Vice President R&D 2015-07-28Sell2,350$21.2-1.75view

Quarterly/Annual Reports about SUPN:

News about SUPN:

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 14 2016
Supernus (SUPN) Reports Encouraging Data from ADHD Study Oct 13 2016
Biotechs Worst-Performing Stocks Wednesday; Prothena, Supernus Fall Oct 12 2016
Supernus ADHD Drug Trial Shows Good Results (SUPN) Oct 12 2016
Blog Coverage Supernus Reports Positive Results from Phase IIb Clinical Trial for SPN 812 Oct 12 2016
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SUPN-US :... Oct 12 2016
Supernus Stock Reverses Downward Despite Good ADHD Drug Trial Oct 11 2016
Nasdaq Leads Sharp Losses As Fiber Optics, Medicals Slide; Biogen Off 2% Oct 11 2016
Here’s Why Supernus Pharmaceuticals, Rent-A-Center and Three Other Stocks are Down Today Oct 11 2016
Supernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD Oct 11 2016
Supernus Announces Positive Results from Phase IIb Clinical Trial For SPN-812 in Children with ADHD Oct 11 2016
Supernus Schedules Conference Call to Present Results of Phase IIb Clinical Trial of SPN-812 in... Oct 10 2016
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Shire, Johnson & Johnson and Supernus... Oct 10 2016
5 Stock Picks Ahead of World Mental Health Day Oct 07 2016
ETF’s with exposure to Supernus Pharmaceuticals, Inc. : September 30, 2016 Sep 30 2016
Stocks Close Barely Higher Ahead Of Fed Announcement; Biotechs Aid Nasdaq Sep 20 2016
Stocks Hold Modest Gains Near Midday; Biotechs Strong Again Sep 20 2016
Nasdaq Erases Gains But Small Caps Strong Ahead Of Fed Sep 19 2016
Seeing the Same Old Patterns Ahead of Fed News Sep 19 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)